. The Clinical Trials and Advocacy Core provides a much needed resource for the successful advancement of our SPORE translational research projects. In addition to supporting the existing SPORE clinical trials, the Core brings the expertise of designing and completing clinical trials to other laboratory investigators who wish to contribute transtational concepts to the SPORE. The active participation of the patient advocates in trial design and accrual strategies represents a unique aspect of the Clinical Trials and Advocacy Core. The Clinical Trials and Advocacy Core has 3 specific aims: 1. To develop a Clinical Trials Resource Core to rapidly design, activate and monitor the four trials/projects proposed in the revised renewal application. The Director and Co-Directors will supervise all aspects of personnel and study management and will assist in the ongoing regulatory processes required for novel translational/interventional studies across multiple institutions within and outside of the SPORE. 2. To provide clinical insight and mentorship to junior faculty and laboratory scientists receiving SPORE pilot and career development funding to aid in the writing of trials and to provide appropriate assistance with regulatory and sponsorship hurdles to more rapidly develop the next generation of translational prostate cancer clinical trials. 3. To support ourAdvocacy/Outreach Program that assists with clinical trial development and accrual of patients, functions as ambassador between the SPORE and various patient advocacy constituencies, and oversees community outreach activities. These goals will be accomplished through meetings of the Core, SPORE investigator meetings, meetings with the Biostatistics/Bioinformatics Core, meetings with individual investigators, community outreach activities and attendance at the National SPORE meetings.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Pascal, Laura E; Masoodi, Khalid Z; O'Malley, Katherine J et al. (2015) 5?-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol 193:1388-93
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Grin, Boris; Loeb, Stacy; Roehl, Kim et al. (2015) A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease. BJU Int 115:101-5
Helenowski, Irene B; Demirtas, Hakan (2014) Multiple imputation of continuous data via a semiparametric probability integral transformation. J Biopharm Stat 24:359-77
Venkatasubramanian, Palamadai N; Brendler, Charles B; Plunkett, Beth A et al. (2014) Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study. Prostate 74:326-35
Adams, Daniel L; Martin, Stuart S; Alpaugh, R Katherine et al. (2014) Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A 111:3514-9
Ai, J; Pascal, L E; O'Malley, K J et al. (2014) Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. Oncogene 33:2286-94
Pavese, Janet M; Ogden, Irene M; Voll, Eric A et al. (2014) Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS One 9:e102289
Kregel, Steven; Szmulewitz, Russell Z; Vander Griend, Donald J (2014) The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate 74:1530-43
Wu, L; Runkle, C; Jin, H-J et al. (2014) CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 33:504-13

Showing the most recent 10 out of 160 publications